We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Sanofi, Regeneron RA Candidate Outperforms Humira in Phase 3 Study
Sanofi, Regeneron RA Candidate Outperforms Humira in Phase 3 Study
Sanofi and Regeneron Pharmaceuticals said their rheumatoid arthritis treatment sarilumab demonstrated superiority over AbbVie’s blockbuster Humira in a Phase 3 Study.